Onconova Therapeutics Inc (NASDAQ:ONTX) major shareholder 683 Capital Management, Llc purchased 200,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average price of $1.04 per share, with a total value of $208,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Onconova Therapeutics Inc (NASDAQ ONTX) opened at $1.03 on Thursday. Onconova Therapeutics Inc has a 52 week low of $0.95 and a 52 week high of $3.88.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded Onconova Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Maxim Group set a $6.00 price target on Onconova Therapeutics and gave the company a “buy” rating in a report on Thursday, November 9th. Finally, HC Wainwright set a $6.00 price target on Onconova Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $7.33.

Several institutional investors have recently made changes to their positions in the company. Sabby Management LLC grew its stake in shares of Onconova Therapeutics by 104.0% during the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after acquiring an additional 399,640 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of Onconova Therapeutics by 21.0% during the third quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 65,140 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Onconova Therapeutics by 58.4% during the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 32,418 shares in the last quarter. Institutional investors own 25.45% of the company’s stock.

WARNING: “Insider Buying: Onconova Therapeutics Inc (ONTX) Major Shareholder Acquires 200,000 Shares of Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/02/15/insider-buying-onconova-therapeutics-inc-ontx-major-shareholder-acquires-200000-shares-of-stock.html.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.